Symbols

AMRN

Amarin·NASDAQ

--(--)

AMRN fundamentals

AMRN Q4 2025 Earnings

Amarin (AMRN) released its earnings on Feb 25, 2026: revenue was 49.22M (YoY -21.00%), missed estimates; EPS was 0 (YoY +100.00%), missed estimates.

Revenue / YoY

49.22M

-21.00%

EPS / YoY

+100.00%

Report date

Feb 25, 2026

AMRN Earnings Call Summary for Q4,2025

Cost Transformation: Achieved $70 million annualized savings, with $303 million cash and no debt, enabling 2026 positive cash flow.
Europe Expansion: $25M upfront Recordati payment, 2026 launches in 6 new markets, and 25% cardiovascular event reduction evidence.
U.S. Resilience: Maintained generics leadership with 30M+ prescriptions, no authorized generic plans, and Q1 2026 volume decline expected.
Scientific Leadership: 45+ publications in 2025, including ACC 2026 presentations on patient subgroup outcomes.

Earnings

EPS

Revenue

Revenue & Expenses

AMRN has released its 2025 Q4 earnings report, with revenue of 49.22M, reflecting a YoY change of -21.00%, and net profit of -1.22M, showing a YoY change of 97.48%. The Sankey diagram below clearly presents AMRN's revenue sources and cost distribution.

Key Indicators

Amarin (AMRN) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Amarin (AMRN)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Amarin (AMRN)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Amarin (AMRN)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown